IMR 687

Drug Profile

IMR 687

Alternative Names: IMR687

Latest Information Update: 01 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lundbeck A/S
  • Developer Imara Inc
  • Class Small molecules
  • Mechanism of Action Phosphodiesterase 9A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Sickle cell anaemia

Most Recent Events

  • 01 Jan 2018 Phase-II clinical trials in Sickle cell anaemia in United Kingdom (PO) (NCT03401112)
  • 17 Oct 2017 Imara completes a phase I trial in Sickle cell anaemia in (In volunteers) in USA (PO) (NCT02998450)
  • 14 Sep 2017 Adverse events data from a phase I trial in Sickle cell anaemia (In volunteers) released by Imara
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top